{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:59:07Z","timestamp":1768287547225,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Limited information is available on the use of biologics in patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) in Japan. The types of biologics, treatment duration, treatment prior to biologics, concomitant treatment, and characteristics of patients receiving biologics were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a Japanese hospital claims database provided by Medical Data Vision Co. (2008\u20132021).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the database, 1186 of 34,207 SSc patients (3.5%) and 620 of 12,303 SSc-ILD patients (5.0%) received anti-interleukin-6 (anti-IL-6) drugs, anti-tumour necrosis factor (anti-TNF) drugs, abatacept, or rituximab. The most common were anti-IL-6 drugs [used in 35.5% of SSc patients and 38.5% of SSc-ILD patients (tocilizumab, 34.5% and 36.6%)], followed by anti-TNF drugs [31.3% and 26.5% (etanercept, 10.5% and 9.0%; others, &amp;lt;8%)], abatacept (17.5% and 20.6%), and rituximab (15.7% and 14.4%). Among SSc and SSc-ILD patients treated with anti-IL-6 drugs, anti-TNF drugs, or abatacept, the most common immunosuppressive drugs prior to initiation of biologics were methotrexate and tacrolimus. Approximately half of patients receiving anti-IL-6 drugs, anti-TNF drugs, or abatacept continued treatment beyond 1\u2009year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study indicates that off-label biologics have been used in a certain number of SSc or SSc-ILD patients in Japan, with tocilizumab the most common.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac055","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:23:41Z","timestamp":1654176221000},"page":"525-532","source":"Crossref","is-referenced-by-count":5,"title":["Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database"],"prefix":"10.1093","volume":"33","author":[{"given":"Yusuke","family":"Narita","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Funatogawa","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Mii","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Tamura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yamakido","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2023092217015768900_R1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2023092217015768900_R2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023092217015768900_R3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"2023092217015768900_R4","author":"Japan Intractable Diseases Information Center (in Japanese)"},{"key":"2023092217015768900_R5","first-page":"2559","article-title":"Immunotherapy of systemic sclerosis","volume":"14","author":"Katsiari","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2023092217015768900_R6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051310","article-title":"Future treatment options in systemic sclerosis\u2014potential targets and ongoing clinical trials","volume":"11","author":"Bohdziewicz","year":"2022","journal-title":"J Clin Med"},{"key":"2023092217015768900_R7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS trial investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2023092217015768900_R8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217015768900_R9","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"2023092217015768900_R10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2023092217015768900_R11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2023092217015768900_R12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: a systematic review","volume":"38","author":"Phumethum","year":"2011","journal-title":"J Rheumatol"},{"key":"2023092217015768900_R13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/imt.13.173","article-title":"Potential use of TNF-\u03b1 inhibitors in systemic sclerosis","volume":"6","author":"Murdaca","year":"2014","journal-title":"Immunotherapy"},{"key":"2023092217015768900_R14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"EULAR Scleroderma Trials and Research group. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023092217015768900_R15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023092217015768900_R16","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2023092217015768900_R17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023092217015768900_R18","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023092217015768900_R19","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/rheumatology\/keaa547","article-title":"Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217015768900_R20","author":"Medical Data Vision Co., Ltd"},{"key":"2023092217015768900_R21","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab111","article-title":"Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database","author":"Funatogawa","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023092217015768900_R22","article-title":"FaSScinate Clinical Trial in Patients With SS. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 24 data from a phase 2\/3 trial","volume":"66","author":"Khanna","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023092217015768900_R23","article-title":"The guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease (in Japanese)","author":"The Japanese Respiratory Society, Japan College of Rheumatology","year":"2020"},{"key":"2023092217015768900_R24","article-title":"The practice guideline for the use of methotrexate for rheumatoid arthritis (in Japanese)","author":"Japan College of Rheumatology","year":"2016"},{"key":"2023092217015768900_R25","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA Group. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023092217015768900_R26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-012-0702-1","article-title":"Management of rheumatoid arthritis: the 2012 perspective","volume":"23","author":"Yamanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2023092217015768900_R27","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2023092217015768900_R28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2023092217015768900_R29","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217015768900_R30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Ebata","year":"2019","journal-title":"J Dermatol"},{"key":"2023092217015768900_R31","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/1346-8138.14189","article-title":"Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide","volume":"45","author":"Numajiri","year":"2018","journal-title":"J Dermatol"},{"key":"2023092217015768900_R32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac136","article-title":"Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan","author":"Isomura","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217015768900_R33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2023092217015768900_R34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac055\/44251555\/roac055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/525\/51715188\/roac055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/525\/51715188\/roac055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T17:33:17Z","timestamp":1695403997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/3\/525\/6598792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac055","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,6,2]]}}}